CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer

The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.  

Coronavirus
• Source: Shutterstock

CureVac AG has stressed that it knew nothing of any offers from the White House for its coronavirus vaccine candidate after a fevered few days for the German biotech firm that have seen two changes of CEO, as it found itself at the center of a media storm in the midst of a pandemic.

“There is no takeover offer from the White House or governmental authorities neither to the technology or to CureVac as a company,” said acting CEO Franz Werner-Haas during a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip